Summary
Pfizer Inc. (PFE) filed an 8-K report on January 29, 2013, to announce its financial results for the fourth quarter and full year of 2012. This filing serves to officially incorporate by reference the press release detailing these results, making them a part of the company's official SEC disclosures. Investors should refer to the press release (Exhibit 99) for the specific financial figures and commentary. The primary purpose of this 8-K filing is informational, providing timely disclosure of Pfizer's operational and financial performance for the concluding period of 2012. While the 8-K itself is brief, it directs stakeholders to the detailed press release for comprehensive insights into revenue, earnings, segment performance, and any forward-looking statements or guidance provided by the company.
Key Highlights
- 1Pfizer announced its Q4 and full-year 2012 financial results on January 29, 2013.
- 2The 8-K filing incorporates by reference the press release containing the detailed financial results.
- 3Exhibit 99 contains the official press release for the Q4 and full-year 2012 financial performance.
- 4This filing fulfills the requirement for timely disclosure of material financial information.
- 5Investors are directed to the press release for specific financial data and operational details.
- 6The filing date is January 29, 2013, with the event date being January 28, 2013.